Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 12.65
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its unique antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. The company was founded in 2017 and is headquartered in Grand Cayman, the Cayman Islands.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Data is available to registered users only
Buy
Sell